Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate

Lyell Immunopharma on Wednesday unveiled initial Phase I data for its investigational CAR-T therapy LYL797, touting promising response rates marred by safety concerns including one patient death.